医学
前列腺癌
肿瘤科
内科学
前列腺
癌症
妇科
临床实习
梅德林
前列腺特异性抗原
风险评估
重症监护医学
肿瘤分期
作者
Daniel E. Spratt,Sandy Srinivas,Nabil Adra,Bilawal Ahmed,Yi An,Rhonda Bitting,Brian Chapin,Heather H. Cheng,Steve Y. Cho,Anthony Victor D’Amico,Neil Desai,T. B. Dorff,James A. Eastham,Thomas A. Farrington,Xin Gao,S Gupta,Joseph E. Ippolito,R. Jeffrey Karnes,Amar U. Kishan,Michael Kuettel
标识
DOI:10.6004/jnccn.2026.0023
摘要
The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and metastatic disease. These NCCN Guidelines Insights summarize the panel's discussions on select 2026 updates to the guidelines regarding nonmetastatic disease: the elimination of the very-low-risk group, updates to the Principles of Active Surveillance, and caution in the use of focal therapy in newly diagnosed patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI